International Journal of Radiation Oncology*Biology*Physics

Journal Information
ISSN / EISSN : 03603016 / 1879355X
Current Publisher: Elsevier BV (10.1016)
Total articles ≅ 68,066
Current Coverage
SCOPUS
PUBMED
MEDLINE
MEDICUS
SCIE
COMPENDEX
Archived in
SHERPA/ROMEO
EBSCO
Filter:

Latest articles in this journal

Zeina Ayoub, Matthew S. Ning, Eric D. Brooks, Jingjing Kang, James W. Welsh, Aileen Chen, Saumil Gandhi, John V. Heymach, Ara A. Vaporciyan, Joe Y. Chang
International Journal of Radiation Oncology*Biology*Physics, Volume 107, pp 261-269; doi:10.1016/j.ijrobp.2020.02.001

The publisher has not yet granted permission to display this abstract.
Shir Schlosser, Rachel Rabinovitch, Z. Shatz, Shira Galper, Ilanit Shahadi-Dromi, Sara Finkel, Galia Jacobson, Adi Rasco, Eitan Friedman, Yael Laitman, et al.
International Journal of Radiation Oncology*Biology*Physics, Volume 107, pp 353-359; doi:10.1016/j.ijrobp.2020.02.020

The publisher has not yet granted permission to display this abstract.
Ivan R. Vogelius, Søren M. Bentzen
International Journal of Radiation Oncology*Biology*Physics, Volume 107, pp 299-304; doi:10.1016/j.ijrobp.2020.01.010

The publisher has not yet granted permission to display this abstract.
Alan Pollack, Felix M. Chinea, Elizabeth Bossart, Deukwoo Kwon, Matthew C. Abramowitz, Charles Lynne, Merce Jorda, Brian Marples, Vivek N. Patel, Xiaodong Wu, et al.
International Journal of Radiation Oncology*Biology*Physics, Volume 107, pp 305-315; doi:10.1016/j.ijrobp.2020.01.052

The publisher has not yet granted permission to display this abstract.
William R. Kennedy, Maria A. Thomas, Jennifer A. Stanley, Jingqin Luo, Laura L. Ochoa, Katherine K. Clifton, Amy E. Cyr, Julie A. Margenthaler, Todd A. DeWees, Alex Price, et al.
International Journal of Radiation Oncology*Biology*Physics, Volume 107, pp 344-352; doi:10.1016/j.ijrobp.2020.02.021

The publisher has not yet granted permission to display this abstract.
Marine Potez, Audrey Bouchet, Mélanie Flaender, Claire Rome, Nora Collomb, Michael Grotzer, Michael Krisch, Valentin Djonov, Jacques Balosso, Emmanuel Brun, et al.
International Journal of Radiation Oncology*Biology*Physics, Volume 107, pp 360-369; doi:10.1016/j.ijrobp.2020.02.023

The publisher has not yet granted permission to display this abstract.
Julie A. Bradley, Daniel J. Indelicato, Haruka Uezono, Christopher G. Morris, Eric Sandler, Hernando De Soto, Raymond B. Mailhot Vega, Ronny Rotondo
International Journal of Radiation Oncology*Biology*Physics, Volume 107, pp 325-333; doi:10.1016/j.ijrobp.2020.01.035

The publisher has not yet granted permission to display this abstract.
Oluwadamilola T. Oladeru, Alice Y. Ho
International Journal of Radiation Oncology*Biology*Physics, Volume 107, pp 233-234; doi:10.1016/j.ijrobp.2020.01.055

Azeem Saleem, Yusuf Helo, Zarni Win, Roger Dale, Jo Cook, Graham E. Searle, Paula Wells
International Journal of Radiation Oncology*Biology*Physics, Volume 107, pp 370-376; doi:10.1016/j.ijrobp.2020.02.014

The publisher has not yet granted permission to display this abstract.
Jakob Kowaliuk, Sina Sarsarshahi, Johanna Hlawatsch, Alexandra Kastsova, Maria Kowaliuk, Alexander Krischak, Peter Kuess, Lisa Duong, Wolfgang Dörr
International Journal of Radiation Oncology*Biology*Physics, Volume 107, pp 377-385; doi:10.1016/j.ijrobp.2020.01.028

Abstract:
This preclinical study aimed to investigate the role of NF-κB in early and late radiogenic sequelae of urinary bladder dysfunction in mice. Thalidomide was applied either during the early or late response phase to determine potential effects of NF-κB inhibition on functional bladder impairment. After pelvic irradiation on day 0, female C3H/Neu mice were observed over a period of 360 days and radiation response was evaluated for alterations in bladder functionality and NF-κB activation. Functionality was determined in graded dose experiments (14-24 Gy) and assessed by micturition frequency analysis (MFA) and transurethral cystotonometry (TC) to reveal alterations in voiding and volume. The induction of the NF-κB proteins p50 and p65 was evaluated by immunohistochemistry in response to a single dose of 23 Gy (ED90). Thalidomide (100 mg/kg/day) was applied intraperitoneally in three treatment groups: daily from day 1-15, daily from day 16-30 or in 2-day-intervals from day 150-180. Immunohistochemical analysis showed a biphasic activation of p50 and p65 during the early radiation cystitis (ERC) phase (day 1-30). After a transient decrease, p50, but not p65, was reactivated permanently leading to increased levels which suggest an occurrence of chronic inflammation in correlation to functional impairment. Both early thalidomide treatments reduced NF-κB activation and shifted the ED50 value for ERC and late radiation sequelae (LRS) to higher doses. These data clearly demonstrate the involvement of NF-κB signaling in the pathogenesis of radiation-induced urinary bladder dysfunction. Additionally, this study emphasizes that biological targeting of early radiogenic processes has enormous impact on chronic symptoms. The late administration of thalidomide showed no significant effect on functionality.
Back to Top Top